Balthasar JP - Search Results

1

Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability.

Nguyen TD, Bordeau BM, Balthasar JP. Nguyen TD, et al. Among authors: balthasar jp. Cancers (Basel). 2023 Jan 24;15(3):713. doi: 10.3390/cancers15030713. Cancers (Basel). 2023. PMID: 36765668 Free PMC article. Review.

2

AAPS workshop report: strategies to address therapeutic protein-drug interactions during clinical development.

Girish S, Martin SW, Peterson MC, Zhang LK, Zhao H, Balthasar J, Evers R, Zhou H, Zhu M, Klunk L, Han C, Berglund EG, Huang SM, Joshi A. Girish S, et al. AAPS J. 2011 Sep;13(3):405-16. doi: 10.1208/s12248-011-9285-6. Epub 2011 Jun 1. AAPS J. 2011. PMID: 21630127 Free PMC article.

3

Monoclonal antibody pharmacokinetics and pharmacodynamics.

Wang W, Wang EQ, Balthasar JP. Wang W, et al. Among authors: balthasar jp. Clin Pharmacol Ther. 2008 Nov;84(5):548-58. doi: 10.1038/clpt.2008.170. Epub 2008 Sep 10. Clin Pharmacol Ther. 2008. PMID: 18784655

4

Prediction of drug bioavailability in humans using immobilized artificial membrane phosphatidylcholine column chromatography and in vitro hepatic metabolic clearance.

Shin BS, Yoon CH, Balthasar JP, Choi BY, Hong SH, Kim HJ, Lee JB, Hwang SW, Yoo SD. Shin BS, et al. Among authors: balthasar jp. Biomed Chromatogr. 2009 Jul;23(7):764-9. doi: 10.1002/bmc.1182. Biomed Chromatogr. 2009. PMID: 19296531

5

Prediction of human pharmacokinetics and tissue distribution of apicidin, a potent histone deacetylase inhibitor, by physiologically based pharmacokinetic modeling.

Shin BS, Bulitta JB, Balthasar JP, Kim M, Choi Y, Yoo SD. Shin BS, et al. Among authors: balthasar jp. Cancer Chemother Pharmacol. 2011 Aug;68(2):465-75. doi: 10.1007/s00280-010-1502-y. Epub 2010 Nov 11. Cancer Chemother Pharmacol. 2011. PMID: 21069337

6

Transient Competitive Inhibition Bypasses the Binding Site Barrier to Improve Tumor Penetration of Trastuzumab and Enhance T-DM1 Efficacy.

Bordeau BM, Yang Y, Balthasar JP. Bordeau BM, et al. Among authors: balthasar jp. Cancer Res. 2021 Aug 1;81(15):4145-4154. doi: 10.1158/0008-5472.CAN-20-3822. Epub 2021 Mar 16. Cancer Res. 2021. PMID: 33727230 Free PMC article.

7

Dynamic Contrast-Enhanced Magnetic Resonance Imaging for the Prediction of Monoclonal Antibody Tumor Disposition.

Bordeau BM, Polli JR, Schweser F, Grimm HP, Richter WF, Balthasar JP. Bordeau BM, et al. Among authors: balthasar jp. Int J Mol Sci. 2022 Jan 8;23(2):679. doi: 10.3390/ijms23020679. Int J Mol Sci. 2022. PMID: 35054865 Free PMC article.

8

Development and Evaluation of Competitive Inhibitors of Trastuzumab-HER2 Binding to Bypass the Binding-Site Barrier.

Bordeau BM, Abuqayyas L, Nguyen TD, Chen P, Balthasar JP. Bordeau BM, et al. Among authors: balthasar jp. Front Pharmacol. 2022 Feb 18;13:837744. doi: 10.3389/fphar.2022.837744. eCollection 2022. Front Pharmacol. 2022. PMID: 35250584 Free PMC article.

9

Targeted Delivery of Endosomal Escape Peptides to Enhance Immunotoxin Potency and Anti-cancer Efficacy.

Polli JR, Chen P, Bordeau BM, Balthasar JP. Polli JR, et al. Among authors: balthasar jp. AAPS J. 2022 Mar 25;24(3):47. doi: 10.1208/s12248-022-00698-x. AAPS J. 2022. PMID: 35338415 Free PMC article.

10

Transient Inhibition of Trastuzumab-Tumor Binding to Overcome the "Binding-Site Barrier" and Improve the Efficacy of a Trastuzumab-Gelonin Immunotoxin.

Chen P, Bordeau BM, Zhang Y, Balthasar JP. Chen P, et al. Among authors: balthasar jp. Mol Cancer Ther. 2022 Oct 7;21(10):1573-1582. doi: 10.1158/1535-7163.MCT-22-0192. Mol Cancer Ther. 2022. PMID: 35930739 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

98 results

Search Page